Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO) have competed for decades. In recent years, these two healthcare leaders ...
Over 18 months, people taking Zepbound lost more weight on average than those on Wegovy, according to the first head-to-head ...
Novo Nordisk's diabetes drug Ozempic has been linked to a rare and serious eye condition that can cause sudden and ...
Some people are not taking weight-loss medications responsibly, the physician says, and don't realize their full implications ...
NVO's CagriSema target of up to 25% in long-term weight loss is highly promising vs. 15% through Wegovy and 20% through ...
The U.S. obesity rate declined for the first time in a decade last year, coinciding with the rise of GLP-1 weight-loss ...
Over half of American adults are eligible for semaglutide, but insurance and other barriers make it hard for people to access ...
New research found that some anti-obesity medications such as Wegovy and Zepbound may prompt people to drink less. These ...
Popular GLP-1 medications like semaglutide in Ozempic and Wegovy help people lose weight, but what should patients know about ...
It’s quickly become evident that GLP-1 drugs for diabetes, weight loss, and more are the new wonder drugs—if only people ...
Britons paying privately for obesity drugs are increasingly choosing Eli Lilly's Mounjaro over Novo Nordisk's Wegovy, online pharmacies say, in a sign the U.S. drugmaker is gaining ground on its ...
Editas plans to lay off 65% of its staff — around 180 employees — as it shelves its lead gene-editing program for sickle cell ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback